All In Biotech

NDA 205054 · Invagen Pharms

Leuprolide Acetate For Depot Suspension

Leuprolide Acetate · Intramuscular

Last checked: Nov 20, 2026Latest source record: Nov 14, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Aug 28, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

457

123 Phase 3, 53 recruiting

FAERS reports

7,124

6,163 serious, 1,141 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 3, 2025.

LUTRATE DEPOT 22.5 mg for 3-month administration (leuprolide acetate) is indicated for treatment of advanced prostate cancer. LUTRATE DEPOT is a gonadotropin-releasing hormone (GnRH) agonist indicated for: Treatment of advanced prostate cancer. ( 1 )

Mechanism: Leuprolide acetate, a GnRH agonist, acts as an inhibitor of gonadotropin secretion. Animal studies indicate that following an initial stimulation, continuous administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis. This effect was reversible upon discontinuation of drug therapy. Administration of leuprolide acetate has resulted in inhibition of the growth of certain hormone dependent tumors (prostate tumors in Noble and Dunning male rats and DMBA-induced mammary tumors in female rats) as well as atrophy of the reproductive organs.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 28, 2023 Supplement 4 · Efficacy LetterLabel
  • Aug 28, 2018 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • LEUPROLIDE ACETATE FOR DEPOT SUSPENSION · LEUPROLIDE ACETATE 22.5MG/VIAL · FOR SUSPENSION, INTRAMUSCULAR · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Leuprolide" as an intervention, any sponsor and status, largest first.

All 457 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue407
  • drug ineffective377
  • off label use326
  • hot flush312
  • fall283
  • asthenia279
  • death274
  • pneumonia248
  • prostate cancer237
  • nausea236
  • anaemia224
  • diarrhoea207

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200483
200596
200685
2007119
2008351
2009153
2010237
2011236
2012308
201374
201472
2015207
2016125
2017135
2018158
2019165
2020205
2021455
2022773
2023781
2024734
2025838
2026734

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 567 on PubMed

Sponsor: Invagen Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.